Since 2002, close to 300 drug candidates to treat Alzheimer's have run into clinical dead ends. But now, having learned from those failures, researchers are testing — and retesting — a batch of the most promising compounds designed to slow the disease's progression. An article in Chemical & Engineering News, the weekly newsmagazine of the American Chemical Society, describes what made this possible and what lies ahead.
